Jordan Luke Green
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jordan Luke Green has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Amy Elizabeth Harwood
Department of Sport and Exercise Sciences, Manchester Metropolitan University, Manchester, UK
2 shared publications - Daniel Carradice
Hull York Medical School, UK; Hull University Teaching Hospitals NHS Trust, Hull, UK
2 shared publications Thomas Cayton
Academic Vascular Surgical Unit, Hull York Medical School/University of Hull, Hull, UK
2 shared publicationsAli Raza
Academic Vascular Surgery Unit, Hull York Medical School, University of Hull, Hull, United Kingdom
1 shared publication- Ali Raza
Academic Vascular Surgical Unit, Hull Royal Infirmary, Hull, UK
1 shared publication - David Alexander Russell
Leeds Vascular Institute, Leeds Teaching Hospitals NHS Trust, Leeds, UK
1 shared publication
Latest Publications
- Open Access
Revascularisation versus amputation for chronic limb-threatening ischaemia: a systematic review and meta-analysis of clinical outcomes and patient characteristics
Background: The relative merits of infrainguinal bypass and primary major lower limb amputation (MLLA) for chronic limb-threatening ischaemia (CLTI) remain uncertain, and the baseline profiles of patients selected for each strategy are poorly described. Methods: A systematic review and meta-analysis were undertaken in accordance with PRISMA 2020 and prospectively registered (PROSPERO: CRD42022356094). MEDLINE, Embase, CENTRAL, and CINAHL were searched from inception to March 2025. Prospective studies of adults with CLTI undergoing primary infrainguinal bypass or primary MLLA were eligible. Mortality, major adverse cardiovascular events (MACE) and subsequent amputation outcomes were synthesised using random-effects meta-analysis of proportions. Baseline comorbidity profiles were also extracted. Results: Twenty-seven studies involving 6,576 patients were included: 5,779 underwent infrainguinal bypass and 797 underwent MLLA. After bypass, pooled mortality was 3.7% at 30 days (95% CI 2.8%–4.9%, I² = 49.4%), 18.5% at 1 year (95% CI 15.6%–21.9%, I² = 62.3%), and 54.3% at 5 years (95% CI 50.5%–58.0%, I² = 0%). After MLLA, pooled mortality was 9.2% at 30 days (95% CI 4.1%–19.3%, I² = 73.5%), 28.5% at 1 year (95% CI 13.3%–51.0, I² = 70.8%), and 39.9% at 2 years (95% CI 0.3%–99.3, I² = 90.5%), although longer-term estimates were limited by sparse data and marked heterogeneity. Thirty-day MACE was 6.5% (95% CI 4.3%–9.7, I² = 63.5%) after bypass and 2.8% after MLLA (95% CI 0.1%–37.6%, I² = 0%). Early subsequent major amputation after bypass occurred in 3.9% of patients (95% CI 2.0%–7.7%, I² = 91.2%), rising to 16.2% at 1 year (95% CI 12.6%–20.5%, I² = 82.0%) and 33.3% at 3 years (95% CI 20.1%–49.8%, I² = 0%). Early re-amputation after MLLA occurred in 10.9% of patients (95% CI 4.5%–24.4%, I² = 40.3%). Baseline comorbidity burden was high in both groups, with substantial heterogeneity across studies. Conclusions: CLTI carries a poor prognosis regardless of treatment strategy. Infrainguinal bypass is associated with lower early mortality and better early limb preservation than primary MLLA, but long-term survival remains poor and later limb failure is common. Primary MLLA is not a low-risk alternative. Better contemporary comparative evidence utilising modern causal inference approaches is needed to support individualised decision-making.
Open AccessRevascularisation versus amputation for chronic limb-threatening ischaemia: a systematic review and meta-analysis of clinical outcomes and patient characteristics
Background: The relative merits of infrainguinal bypass and primary major lower limb amputation (MLLA) for chronic limb-threatening ischaemia (CLTI) remain uncertain, and the baseline profiles of patients selected for each strategy are poorly described. Methods: A systematic review and meta-analysis were undertaken in accordance with PRISMA 2020 and prospectively registered (PROSPERO: CRD42022356094). MEDLINE, Embase, CENTRAL, and CINAHL were searched from inception to March 2025. Prospective studies of adults with CLTI undergoing primary infrainguinal bypass or primary MLLA were eligible. Mortality, major adverse cardiovascular events (MACE) and subsequent amputation outcomes were synthesised using random-effects meta-analysis of proportions. Baseline comorbidity profiles were also extracted. Results: Twenty-seven studies involving 6,576 patients were included: 5,779 underwent infrainguinal bypass and 797 underwent MLLA. After bypass, pooled mortality was 3.7% at 30 days (95% CI 2.8%–4.9%, I² = 49.4%), 18.5% at 1 year (95% CI 15.6%–21.9%, I² = 62.3%), and 54.3% at 5 years (95% CI 50.5%–58.0%, I² = 0%). After MLLA, pooled mortality was 9.2% at 30 days (95% CI 4.1%–19.3%, I² = 73.5%), 28.5% at 1 year (95% CI 13.3%–51.0, I² = 70.8%), and 39.9% at 2 years (95% CI 0.3%–99.3, I² = 90.5%), although longer-term estimates were limited by sparse data and marked heterogeneity. Thirty-day MACE was 6.5% (95% CI 4.3%–9.7, I² = 63.5%) after bypass and 2.8% after MLLA (95% CI 0.1%–37.6%, I² = 0%). Early subsequent major amputation after bypass occurred in 3.9% of patients (95% CI 2.0%–7.7%, I² = 91.2%), rising to 16.2% at 1 year (95% CI 12.6%–20.5%, I² = 82.0%) and 33.3% at 3 years (95% CI 20.1%–49.8%, I² = 0%). Early re-amputation after MLLA occurred in 10.9% of patients (95% CI 4.5%–24.4%, I² = 40.3%). Baseline comorbidity burden was high in both groups, with substantial heterogeneity across studies. Conclusions: CLTI carries a poor prognosis regardless of treatment strategy. Infrainguinal bypass is associated with lower early mortality and better early limb preservation than primary MLLA, but long-term survival remains poor and later limb failure is common. Primary MLLA is not a low-risk alternative. Better contemporary comparative evidence utilising modern causal inference approaches is needed to support individualised decision-making.
- 1 October 2019
- Published by Acoustical Society of America (ASA) in The Journal of the Acoustical Society of America
- Vol. 146 (4_Suppleme) , 2923
Acoustic correlates of comorbid voice and resonance impairment in individuals with amyotrophic lateral sclerosis
Assessment of voice and resonance impairment in amyotrophic lateral sclerosis (ALS) may be challenging due to multi-speech subsystem involvement. Although several acoustic measures have been associated with isolated voice and resonance impairment, their efficacy in the presence of comorbid voice-resonance impairment is unclear. The goal of this work is to determine acoustic features that correlate with perceptual judgment of voice and resonance severity in patients with ALS, and identify measures capable of differentiating phonatory, resonance, and co-occurring impairments. Two listeners rated resonance and voice impairment severity of repetitions of “Buy Bobby a puppy” produced by 26 participants with ALS. Samples were stratified based on perceptual ratings: bulbar asymptomatic, predominantly phonatory involvement (i.e., abnormal voice), predominantly resonatory involvement (hypernasality), and mixed (phonatory and resonance involvement). Groups were compared using resonance (one-third octave analysis) and phonatory (cepstral/spectral) measures. The one-third octave analysis differentiated all groups (p < 0.05); the cepstral peak prominence differentiated all groups (p < 0.01) except asymptomatic versus mixed; and the low/high spectral ratio did not differ between groups. Findings illustrate the challenges of implementing targeted resonance and voice measures in the presence of multi-speech system involvement, though one-third octave analysis is a promising approach to quantifying voice and resonance impairment in ALS.
- 1 October 2019
- Published by Acoustical Society of America (ASA) in The Journal of the Acoustical Society of America
- Vol. 146 (4_Suppleme) , 2923
Acoustic correlates of comorbid voice and resonance impairment in individuals with amyotrophic lateral sclerosis
Assessment of voice and resonance impairment in amyotrophic lateral sclerosis (ALS) may be challenging due to multi-speech subsystem involvement. Although several acoustic measures have been associated with isolated voice and resonance impairment, their efficacy in the presence of comorbid voice-resonance impairment is unclear. The goal of this work is to determine acoustic features that correlate with perceptual judgment of voice and resonance severity in patients with ALS, and identify measures capable of differentiating phonatory, resonance, and co-occurring impairments. Two listeners rated resonance and voice impairment severity of repetitions of “Buy Bobby a puppy” produced by 26 participants with ALS. Samples were stratified based on perceptual ratings: bulbar asymptomatic, predominantly phonatory involvement (i.e., abnormal voice), predominantly resonatory involvement (hypernasality), and mixed (phonatory and resonance involvement). Groups were compared using resonance (one-third octave analysis) and phonatory (cepstral/spectral) measures. The one-third octave analysis differentiated all groups (p < 0.05); the cepstral peak prominence differentiated all groups (p < 0.01) except asymptomatic versus mixed; and the low/high spectral ratio did not differ between groups. Findings illustrate the challenges of implementing targeted resonance and voice measures in the presence of multi-speech system involvement, though one-third octave analysis is a promising approach to quantifying voice and resonance impairment in ALS.
- Open Access
- 3 May 2018
- Published by SAGE Publications in Vascular
- Vol. 26 (5) , 531-539
Extracorporeal shockwave therapy for intermittent claudication: Medium-term outcomes from a double-blind randomised placebo-controlled pilot trial
Peripheral arterial disease most commonly presents as intermittent claudication (IC). Early evidence has suggested that extracorporeal shockwave therapy is efficacious in the short term for the management of intermittent claudication. The objective of this pilot trial was to evaluate the medium-term efficacy of this treatment. This double-blind randomised placebo-controlled pilot trial randomised patients with unilateral intermittent claudication in a 1:1 fashion to receive extracorporeal shockwave therapy or a sham treatment for three sessions per week over three weeks. Primary outcomes were maximum walking distance and intermittent claudication distance using a fixed-load treadmill test. Secondary outcomes included pre- and post-exertional ankle-brachial pressure indices, safety and quality of life assessed using generic (SF36, EQ-5D-3L) and disease-specific (vascular quality of life) measures. All outcome measures were assessed at 12 months post-treatment. Thirty participants were included in the study (extracorporeal shockwave therapy, n = 15; sham, n = 15), with 26 followed up and analysed at 12 months (extracorporeal shockwave therapy, n = 13; sham, n = 13). Intragroup analysis demonstrated significant improvements in maximum walking distance, intermittent claudication distance and post-exertional ankle-brachial pressure indices (p < 0.05) in the active treatment group, with no improvements in pre-exertional ankle-brachial pressure indices. Significant improvements in quality of life were observed in 3 out of 19 domains assessed in the active group. A re-intervention rate of 26.7% was seen in both groups. These findings suggest that extracorporeal shockwave therapy is effective in improving walking distances at 12 months. Although this study provides important pilot data, a larger study is needed to corroborate these findings and to investigate the actions of this treatment. ISRCTN: NCT02652078.
- 3 May 2018
- Published by SAGE Publications in Vascular
- Vol. 26 (5) , 531-539
Open AccessExtracorporeal shockwave therapy for intermittent claudication: Medium-term outcomes from a double-blind randomised placebo-controlled pilot trial
Peripheral arterial disease most commonly presents as intermittent claudication (IC). Early evidence has suggested that extracorporeal shockwave therapy is efficacious in the short term for the management of intermittent claudication. The objective of this pilot trial was to evaluate the medium-term efficacy of this treatment. This double-blind randomised placebo-controlled pilot trial randomised patients with unilateral intermittent claudication in a 1:1 fashion to receive extracorporeal shockwave therapy or a sham treatment for three sessions per week over three weeks. Primary outcomes were maximum walking distance and intermittent claudication distance using a fixed-load treadmill test. Secondary outcomes included pre- and post-exertional ankle-brachial pressure indices, safety and quality of life assessed using generic (SF36, EQ-5D-3L) and disease-specific (vascular quality of life) measures. All outcome measures were assessed at 12 months post-treatment. Thirty participants were included in the study (extracorporeal shockwave therapy, n = 15; sham, n = 15), with 26 followed up and analysed at 12 months (extracorporeal shockwave therapy, n = 13; sham, n = 13). Intragroup analysis demonstrated significant improvements in maximum walking distance, intermittent claudication distance and post-exertional ankle-brachial pressure indices (p < 0.05) in the active treatment group, with no improvements in pre-exertional ankle-brachial pressure indices. Significant improvements in quality of life were observed in 3 out of 19 domains assessed in the active group. A re-intervention rate of 26.7% was seen in both groups. These findings suggest that extracorporeal shockwave therapy is effective in improving walking distances at 12 months. Although this study provides important pilot data, a larger study is needed to corroborate these findings and to investigate the actions of this treatment. ISRCTN: NCT02652078.
- 1 February 2018
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 67 (2) , 514-521.e2
A feasibility double-blind randomized placebo-controlled trial of extracorporeal shockwave therapy as a novel treatment for intermittent claudication
- 1 February 2018
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 67 (2) , 514-521.e2
A feasibility double-blind randomized placebo-controlled trial of extracorporeal shockwave therapy as a novel treatment for intermittent claudication